ANNE WOJCICKI
Co-founded 23andMe, the direct-to-consumer genetic testing company that made DNA kits a mainstream phenomenon.
Anne Wojcicki convinced 14 million people to spit in a tube and mail their DNA to a startup. 23andMe turned that saliva into the world's largest genetic database, briefly hit a $6 billion valuation via SPAC, and then watched its stock fall 97%. She is now trying to take the company private to save it. The woman who democratized genetic testing may end up being a case study in why SPACs were a terrible idea for companies that weren't ready for public markets.
Net Worth
$400 million
Nationality
American
Time Horizon
Long-Term
Risk Appetite
8 / 10
CAREER & BACKGROUND
Born in 1973 in San Mateo County, California. Her mother was an educator, and her father was a physics professor at Stanford.
Her sister, Susan Wojcicki, was the CEO of YouTube until her death in 2024. Anne studied biology at Yale, then worked on Wall Street as a healthcare analyst at Investor AB and Passport Capital before co-founding 23andMe in 2006.
The idea was radical at the time: let regular people access their own genetic information without going through a doctor. The first 23andMe kit cost $999 when it launched.
The FDA initially blocked the company from providing health-related results in 2013, calling the tests unapproved medical devices. Wojcicki spent two years working with regulators to get approval back.
23andMe went public via SPAC in 2021 at a $3.5 billion valuation, peaked at $6 billion, and then collapsed. By 2024, the stock was below $1.
The company struggled to find a profitable business model beyond one-time DNA kit sales, and a massive data breach in 2023 compromised 7 million users' genetic data. Wojcicki announced plans to take 23andMe private in 2024.
COMPANIES & ROLES
Co-founded 23andMe in 2006. Grew it to 14+ million customers and the world's largest consumer genetic database.
Took the company public via SPAC merger with VG Acquisition Corp in 2021. Board member of multiple biotech companies.
Previously worked at Passport Capital (hedge fund) as a healthcare-focused analyst.
INVESTING STYLE & PHILOSOPHY
Mission-driven and long-term. Wojcicki is not a financial engineer — she is a scientist who built a company around a belief that people deserve access to their own genetic data.
Her investment approach inside 23andMe has been to reinvest heavily in drug development using the genetic database, hoping to create a pharmaceutical revenue stream.
THE PLAYBOOK
Risk Approach
High. She bet her career on a product the FDA initially banned.
She took the company public via SPAC at what turned out to be the worst possible time. She is now trying to take it private at a massive discount.
Wojcicki takes existential risks, but they are driven by conviction in the mission, not financial recklessness.
Money Habits
Lives in the Bay Area. Was married to Google co-founder Sergey Brin from 2007 to 2015 — one of the most powerful couples in Silicon Valley.
Despite the divorce, she has maintained a low-key lifestyle relative to her net worth. Known for being personally involved in 23andMe's product decisions.
BIGGEST WIN
Getting the FDA to reverse its ban on health-related genetic testing. In 2013, the FDA ordered 23andMe to stop selling health reports.
By 2017, Wojcicki had worked with regulators to become the first FDA-authorized direct-to-consumer genetic health risk test. She turned an existential threat into a competitive moat — no competitor has matched 23andMe's regulatory clearance breadth.
BIGGEST MISTAKE
The SPAC and subsequent stock collapse. 23andMe went public at a $3.5 billion valuation and peaked near $6 billion.
By late 2024, the market cap had fallen below $200 million — a 97% decline. The company never figured out how to make customers come back after their initial DNA test, and the 2023 data breach eroded trust.
FINANCIAL PHILOSOPHY
Data is the most valuable asset in healthcare. Wojcicki's thesis is that a genetic database of millions of people is worth more than any single drug.
If 23andMe can use that data to develop pharmaceuticals, the one-time DNA kit revenue becomes a rounding error.
FAMILY & PERSONAL LIFE
Was married to Sergey Brin (co-founder of Google) from 2007 to 2015. Two children together.
Her sister, Susan Wojcicki, was CEO of YouTube until her death in August 2024. Her mother, Esther Wojcicki, is an educator and author known for raising three extremely successful daughters.
EDUCATION
Yale University (BS in Biology). Worked on Wall Street before pivoting to biotech entrepreneurship.
Her academic background in biology — not business — shaped 23andMe's science-first approach.
BOOKS & RESOURCES
The definitive book on genetics that aligns with 23andMe's mission
Written by Anne's mother about raising her and her sisters
The cancer biography that connects to 23andMe's health research ambitions
As an Amazon Associate, Netfigo earns from qualifying purchases. Book links above may be affiliate links.
QUOTES (5)
A database of 14 million genomes is the most valuable asset in medicine. The question is how we use it responsibly.
People have a right to their own genetic information. It shouldn't be locked behind a doctor's gatekeeper.
The FDA told us to stop selling our product. Instead of giving up, we spent two years proving them wrong.
Going public via SPAC seemed like a good idea at the time. In hindsight, we needed more time to figure out recurring revenue.
NETFIGO SCORE
Proprietary 5-dimension investor rating
Risk Appetite
Contrarian Index
Track Record
Accessibility
Time Horizon
Related Profiles
Head-to-Head
Compare Anne Wojcicki vs another investor.